全文获取类型
收费全文 | 181041篇 |
免费 | 13433篇 |
国内免费 | 4333篇 |
专业分类
耳鼻咽喉 | 1379篇 |
儿科学 | 2606篇 |
妇产科学 | 3076篇 |
基础医学 | 24136篇 |
口腔科学 | 3709篇 |
临床医学 | 12363篇 |
内科学 | 22663篇 |
皮肤病学 | 2207篇 |
神经病学 | 12137篇 |
特种医学 | 6442篇 |
外国民族医学 | 2篇 |
外科学 | 14924篇 |
综合类 | 24321篇 |
现状与发展 | 23篇 |
一般理论 | 8篇 |
预防医学 | 14761篇 |
眼科学 | 2258篇 |
药学 | 25837篇 |
54篇 | |
中国医学 | 12857篇 |
肿瘤学 | 13044篇 |
出版年
2024年 | 163篇 |
2023年 | 2176篇 |
2022年 | 3085篇 |
2021年 | 7429篇 |
2020年 | 6104篇 |
2019年 | 6077篇 |
2018年 | 6155篇 |
2017年 | 6780篇 |
2016年 | 6870篇 |
2015年 | 6408篇 |
2014年 | 7208篇 |
2013年 | 11212篇 |
2012年 | 9064篇 |
2011年 | 10942篇 |
2010年 | 6866篇 |
2009年 | 7030篇 |
2008年 | 8580篇 |
2007年 | 9493篇 |
2006年 | 8999篇 |
2005年 | 8365篇 |
2004年 | 7179篇 |
2003年 | 6433篇 |
2002年 | 5105篇 |
2001年 | 4576篇 |
2000年 | 3847篇 |
1999年 | 3274篇 |
1998年 | 2592篇 |
1997年 | 2685篇 |
1996年 | 2295篇 |
1995年 | 2150篇 |
1994年 | 2069篇 |
1993年 | 1740篇 |
1992年 | 1609篇 |
1991年 | 1522篇 |
1990年 | 1305篇 |
1989年 | 1075篇 |
1988年 | 1031篇 |
1987年 | 944篇 |
1986年 | 861篇 |
1985年 | 1268篇 |
1984年 | 1021篇 |
1983年 | 773篇 |
1982年 | 797篇 |
1981年 | 662篇 |
1980年 | 645篇 |
1979年 | 509篇 |
1978年 | 321篇 |
1977年 | 291篇 |
1976年 | 260篇 |
1975年 | 196篇 |
排序方式: 共有10000条查询结果,搜索用时 230 毫秒
111.
Micro‐evolution of the hepatitis B virus genome in hepatitis B e‐antigen‐positive carriers: Comparison of genotypes B and C at various immune stages 下载免费PDF全文
112.
Kun Ma Jiayun Liu Youjin Wang Yubin Zhong Zhenfeng Wu Ruiying Fan Shanfeng Guo 《Journal of gastrointestinal oncology.》2020,11(6):1350
BackgroundOur study aims to investigate changes in cell-free DNA (cfDNA) concentration and integrity in primary hepatocellular carcinoma (PHC) patients before and after transcatheter arterial chemoembolization (TACE) treatment and their influence on the evaluation of prognosis of the disease.MethodsA total of 84 PHC patients admitted to the Affiliated Hospital of Nanjing University of Chinese Medicine from December 2016 to December 2017 were included as the study group, while 55 healthy people served as the control group. Plasma cfDNA concentration and integrity were determined using qRT-PCR. The correlation between cfDNA concentration/integrity and clinical characteristics of PHC patients were analyzed. A ROC curve was used to investigate the sensitivity and specificity of cfDNA as detection indices. Univariate and multivariate analyses were used to analyze factors affecting recurrence in PHC patients and compare recurrence-free survival (RFS) of PHC patients with high cfDNA expression and low cfDNA expression.ResultsPlasma cfDNA concentration and integrity were significantly higher in PHC patients before TACE treatment than in healthy people and significantly lower after treatment than before (P<0.05). The cfDNA concentration was significantly correlated with tumor size, lymph node metastasis, TNM stage, and BCLC stage, while cfDNA integrity was significantly correlated with tumor size, TNM stage, and BCLC stage (P<0.05). ROC results showed that the area under the curve (AUC) value of cfDNA concentration was the largest, with an optimal cut-off of 10.51 ng/mL. Multivariate regression analysis for COX showed that the TNM stage, cfDNA concentration, and AFP were independent risk factors that affected PHC patients’ survival.ConclusionsPlasma cfDNA concentration in PHC patients is more sensitive and specific than any other tumor marker. It is an independent risk factor for PHC patients treated with TACE. Therefore, it is hypothesized cfDNA is a potential biomarker for prognostic evaluation of PHC patients treated with TACE. 相似文献
113.
114.
115.
目的:回顾性分析芪地固肾方治疗特发性膜性肾病(IMN)的临床疗效与安全性。方法:选取2014年1月至2017年6月陕西中医药大学附属医院肾病科门诊及住院IMN患者141例,根据用药方案分为西药组(西药标准疗法)、中西药结合组(芪地固肾方+西药标准疗法)和中药组(芪地固肾方)3组各47例,观察3组患者治疗后临床疗效、复发率及不良反应等。结果:治疗6个月后,中西药结合组和西药组总有效率72.34%、68.09%高于中药组,治疗12个月时3组有效率比较差异无统计学意义,治疗18个月后中药组和中西药结合组总有效率75.76%、78.72%高于西药组。中药组和中西药结合组在治疗12个月和18个月后较西药组在提高中医证候疗效、减少中医证候积分上更具优势。中药组和中西药结合组复发率更低,3组均未出现严重不良反应。结论:芪地固肾方能提高IMN缓解率,在提高中医证候疗效、降低复发率上更具优势,远期疗效可观,值得进一步推广应用。 相似文献
116.
王俊平 《中国继续医学教育》2020,(3):183-185
目的探讨对冠心病心绞痛患者给予健康教育联合心理护理干预后对其生活质量等方面产生的影响。方法选择我院2017年4月-2019年2月收治的100例冠心病心绞痛患者作为实验对象;抽签法分组后探究每组患者护理方式;对照组(50例):选择基础护理方式展开疾病护理;试验组(50例):选择基础护理+健康教育+心理护理方式展开疾病护理;对比各组患者表现出的护理工作满意度以及生活质量评定差异。结果试验组冠心病心绞痛患者护理工作总满意度(98.00%)高于对照组(82.00%)明显(P<0.05);试验组冠心病心绞痛患者睡眠情感、社会生活、精力以及躯体活动评分均高于对照组(P<0.05)。结论冠心病心绞痛患者在接受临床护理工作期间,对于护理工作满意度的提升,各项生活质量指标(睡眠情感、社会生活、精力以及躯体活动)评分结果的提升,均获得明显作用效果,最终对于冠心病心绞痛患者生活质量以及康复状态的显著提升,奠定基础。 相似文献
117.
118.
Treatment of posterior eye diseases is more challenging than the anterior segment ailments due to a series of anatomical barriers and physiological constraints confronted by drug delivery to the back of the eye. In recent years, concerted efforts in drug delivery have been made to prolong the residence time of drugs injected in the vitreous humor of the eye. Our previous studies demonstrated that poly(ortho ester) (POE) nanoparticles were biodegradable/biocompatible and were capable of long-term sustained release. The objective of the present study was to investigate the safety and localization of POE nanoparticles in New Zealand white rabbits and C57BL/6 mice after intravitreal administration for the treatment of chronic posterior ocular diseases. Two concentration levels of POE nanoparticles solution were chosen for intravitreal injection: 1.5?mg/ml and 10?mg/ml. Our results demonstrate that POE nanoparticles were distributed throughout the vitreous cavity by optical coherence tomography (OCT) examination 14 days post-intravitreal injection. Intraocular pressure was not changed from baseline. Inflammatory or adverse effects were undetectable by slit lamp biomicroscopy. Furthermore, we demonstrate that POE nanoparticles have negligible toxicity assessed at the cellular level evidenced by a lack of glia activation or apoptosis estimation after intravitreal injection. Collectively, POE nanoparticles are a novel and nontoxic as an ocular drug delivery system for the treatment of posterior ocular diseases. 相似文献
119.
Ana M. Gómez Angelica Imitola Diana Henao Maira García-Jaramillo Marga Giménez Clara Viñals Bruno Grassi Mariana Torres Isabella Zuluaga Oscar Mauricio Muñoz Martin Rondón Fabián León-Vargas Ignacio Conget 《Diabetes & Metabolic Syndrome: Clinical Research & Reviews》2021,15(1):267-272
Background and aimsDespite using sensor-augmented pump therapy (SAPT) with predictive low-glucose management (PLGM), hypoglycemia is still an issue in patients with type 1 Diabetes (T1D). Our aim was to determine factors associated with clinically significant hypoglycemia (<54 mg/dl) in persons with T1D treated with PLGM-SAPT.Methodology: This is a multicentric prospective real-life study performed in Colombia, Chile and Spain. Patients with T1D treated with PLGM-SAPT, using sensor ≥70% of time, were included. Data regarding pump and sensor use patterns and carbohydrate intake from 28 consecutive days were collected. A bivariate and multivariate Poisson regression analysis was carried out, to evaluate the association between the number of events of <54 mg/dl with the clinical variables and patterns of sensor and pump use.Results188 subjects were included (41 ± 13.8 years-old, 23 ± 12 years disease duration, A1c 7.2% ± 0.9). The median of events <54 mg/dl was four events/patient/month (IQR 1–10), 77% of these events occurred during day time. Multivariate analysis showed that the number of events of hypoglycemia were higher in patients with previous severe hypoglycemia (IRR1.38; 95% CI 1.19–1.61; p < 0.001), high glycemic variability defined as Coefficient of Variation (CV%) > 36% (IRR 2.09; 95%CI 1.79–2.45; p < 0.001) and hypoglycemia unawareness. A protector effect was identified for adequate sensor calibration (IRR 0.77; 95%CI 0.66–0.90; p:0.001), and the use of bolus wizard >60% (IRR 0.74; 95%CI 0.58–0.95; p:0.017).ConclusionIn spite of using advanced SAPT, clinically significant hypoglycemia is still a non-negligible risk. Only the identification and intervention of modifiable factors could help to prevent and reduce hypoglycemia in clinical practice. 相似文献